Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06238622 · ClinicalTrials.gov registry record · Phase 3
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
A Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, sponsored by Boehringer Ingelheim.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,700
- Enrollment target
- 20
- Study locations
NCT06238622 is a Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis that is actively recruiting participants, run by Boehringer Ingelheim. The registered enrollment target is 1,700 participants, above the 718-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (137% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06238622, a Phase 3 study of Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis, is actively recruiting participants, sponsored by Boehringer Ingelheim.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,700 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests.
Conditions Studied
Interventions
- DRUG Nerandomilast
Study Locations (20)
California
- University of Southern California - Los Angeles
- Cedars-Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
- University of California Davis - Sacramento
Florida
- St. Francis Medical Institute - Clearwater
- University of Florida - Gainesville
- Clinical Research Specialists LLC - Kissimmee - Kissimmee
- Advanced Pulmonary Research Institute - Loxahatchee Groves
Georgia
- Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead - Atlanta
- The Emory Clinic - Atlanta
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- University of Arizona - Tucson
Colorado
- National Jewish Health - Denver
Connecticut
- Yale University School of Medicine - New Haven
Delaware
- Christiana Hospital - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,700 participants |
| Start Date | 2024-05-06 |
| Est. Completion | 2027-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06238622
The ClinicalTrials.gov registry entry for NCT06238622 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 718-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (137% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Nerandomilast is the first listed.
NCT06238622 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06238622 about?
NCT06238622 is a clinical study titled "A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast". This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with ...
What is the current status of trial NCT06238622?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,700 participants. The study started on 2024-05-06. Estimated completion is 2027-05-05.
What conditions does trial NCT06238622 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis.
What interventions are being tested in trial NCT06238622?
The interventions under investigation include: Nerandomilast (DRUG).
Who is sponsoring clinical trial NCT06238622?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06238622 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 3
-
Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
COMPLETED · Phase 3
-
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
COMPLETED · Phase 3
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RECRUITING · Early Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.